Antitrust difficulties weigh on US cannabis stocks, but is it sufficient to unravel offers?


The U.S. cannabis market has noticed billions of dollars of acquisitions in current months, attracting scrutiny from federal trustbusters examining irrespective of whether planned purchases could quash competitors in the emerging marijuana market.

The U.S. Division of Justice’s evaluation of the offers – which includes these involving Chicago-primarily based Cresco Labs (CSE: CL OTC: CRLBF) and Arizona-primarily based Harvest Overall health &amp Recreation (CSE: HARV OTC: HRVSF) – is weighing on cannabis stocks and triggering issues irrespective of whether some of the purchases could unravel.

The scrutiny has raised concerns about the Justice Division (DOJ)’s apparent acknowledgement of an market that remains illegal below federal law.

Cannabis providers, as in any other market topic to detailed antitrust investigation, are essential to list income amounts below so-named NAICS codes (North American Sector Classification Method).

“At 1st glance, it appears ironic that a federal agency is reviewing transactions in a federally illegal market, but primarily based on sizable public business involvement and the worth of these transactions, it would seem that, by default, these offers would qualify for evaluation,” Jesse Pytlak, equity analyst at Toronto-primarily based Cormark Securities, told Marijuana Small business Each day.

The wave of offers involves:

Second requests

In numerous instances, the DOJ issued second requests for information and facts from the providers below the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

The requests can lead to months of more documentation aimed at figuring out if offers would violate the law.

“The uncertainty is incredibly injurious to the target company. It is eight or nine months of uncertainty,” Larry Silverman, companion at Miami-primarily based law firm Akerman, told MJBizDaily.

“The mere issuance of these (second requests) kills a heavy percentage of these offers.”

Here’s additional about how the requests can impact organizations:

  • Thousands of merger or acquisition offers are proposed just about every year, but ordinarily much less than five% ever obtain a second evaluation notice – which can take months, and millions of dollars, to resolve.
  • The extended uncertainty can negatively influence a company’s relationships with its personnel, prospects, suppliers and competitors.
  • Faced with these more dangers, purchasers and sellers may perhaps decide on to abandon proposed offers.

Situations of providers getting a DOJ second request involve the planned Cresco/Origin Residence and Harvest Overall health/Verano Holdings deals.

A MedMen/PharmaCann transaction also has reportedly received a request – although the providers did not confirm.

Target providers in offers which includes Cura Partners and Origin Residence declined to comment.

PharmaCann, an Illinois-primarily based multistate health-related marijuana business that is the topic of a $682 million acquisition by California-primarily based MedMen (CSE: MMEN OTC: MMNFF), stated it is seeking forward to closing the transaction “in due course.”

MedMen – whose stock declined from 9.02 Canadian dollars ($six.86) a week right after the PharmaCann deal was announced to effectively below CA$three a share now – did not respond to inquiries.

Pushing on

Cannabis providers are moving forward with acquisitions, confident offers will close – although delayed.

For instance, Harvest Overall health announced March 11 it will obtain multistate operator Verano Holdings in what was then estimated as an $850 million deal.

Harvest subsequently received a second request from the DOJ, Harvest’s Christine Hersey, director of investor relations, confirmed.

Rather of closing the deal in the 1st half of 2019 as initially predicted March 11, Harvest is now aiming for the finish of this year, she stated.

From a higher of pretty much CA$14 a share shortly right after the deal was announced, Harvest stock is now trading closer to CA$six.80.

“Most of the sector is down from its earlier highs,” Hersey stated. “The issues have impacted all the providers that have acquisitions pending.”

Analysts agree.

Whilst other elements contribute to the sector decline, it is clear the incredibly notion of federal authorities inserting themselves into cannabis regulation is a drag on stocks.

Brett Hundley, senior analyst at New York-primarily based Seaport International, wrote in a note July 23 that promoting stress is in aspect due to “regulatory disappointment.”

Andrew Kessner, equity analysis analyst at New York-primarily based William O’Neil, wrote in a note right after Curaleaf’s announcement it is obtaining Grassroots:

“One of the crucial elements weighing on U.S. cannabis stocks has been the DOJ’s requests for more information and facts associated to pending acquisitions by other MSOs.”

Cresco, which reported June 10 its planned acquisition of Origin Residence is topic to a second request from the DOJ, saw its stock dip from a current higher of CA$17.75 about 3 weeks right after the April 1 deal announcement to CA$10.59 on July 30.

Its target, Origin Residence, was valued at CA$12.98 April 29 but trading at just CA$7.26 on July 30.

The original $823 million worth of the deal was predicated on valuing Origin Residence shares at CA$12.68.

Whilst the deal was initially anticipated to close at the finish of June, Cresco is now aiming for Oct. 31, according to a current business filing.

Overstated aspect?

The reality of antitrust difficulties may perhaps be overblown, some specialists stated.

Kessner at William O’Neil wrote in his note that regional regulatory issues are potentially additional of an situation.

“We’ve also observed state lawmakers and regulators becoming increasingly conscious of, and averse to, the thought of ‘Big Marijuana’ dominating state markets,” he wrote.

“We view this dynamic as a considerably bigger danger to the development prospective for MSOs than antitrust evaluations or other federal level difficulties.”

Evan Eneman, CEO of expert solutions business MGO/Ello Alliance, welcomed the interest from federal authorities but stated the actual danger is low.

His colleague, Hershel Gerson, CEO of new cannabis investment bank Ello Capital, stated any antitrust issues had been largely unfounded simply because no interstate commerce was involved.

“Things are so regionalized that it is really hard to make an argument that somebody is generating a monopoly,” he stated. “There is a lot of maturing to do in this market.”

And Curaleaf’s announcement of the Grassroots acquisition calmed the market place, as well. Curaleaf management expressed self-assurance the footprint of the deal would not raise antitrust issues.

On the other hand, there is a lengthy way to go, and target providers in specific may perhaps just get to a tipping point exactly where the deal is not worth following by way of on.

With stock rates continuing to have a pall cast on them, target providers may perhaps really feel a mixture of the uncertainty and declining values of any deal may perhaps detract from the bluster of comments in the wake of multimillion-dollar-deal announcements.

Craig Behnke, equity analyst at MJBizDaily, contributed to this story. Jeff Smith, MJBizDaily’s legal and regulatory reporter, also contributed some reporting.

Nick Thomas can be reached at [email protected]

Get access to additional in-depth market place evaluation, premium capabilities on cannabis investing trends and month-to-month executive webcasts with an Investor Intelligence subscription.


Latest posts